Key result
Single-transcript mRNA vaccine protects mice against EV-D68 challenge by generating neutralizing antibodies.
Why the study?
Previous EV-D68 VLP mRNA vaccines required co-administering two mRNA-LNPs, presenting challenges in manufacturing and quality control.
Answers are grounded in this paper and cite their sources.
A single-transcript mRNA vaccine for EV-D68 successfully induces protective immunity in mice, offering a simpler manufacturing alternative to dual-mRNA systems.
Enterovirus D68 (EV-D68) causes pediatric respiratory illness and is linked to acute flaccid myelitis (AFM), posing a global health threat. We have previously reported that an mRNA vaccine expressing a virus-like particle (VLP) of EV-D68, which co-administers two mRNA-lipid nanoparticles (LNPs) encoding the viral structural protein P1 and viral protease 3CD, conferred protection against infection. Nonetheless, the requirement for two mRNA-LNPs presents challenges in manufacturing and quality control. Here, we investigated the potential of single mRNA constructs encoding both P1 and 3CD, connected by linker sequences. mRNA constructs encoding both P1 and 3CD in a single transcript were designed with linkers such as 2A peptides, 3CD protease cleavage sites (CS), combinations of 2A peptides and CS, or internal ribosome entry sites (IRES). Constructs using 2A, CS, and combinations of 2A and CS successfully induced the production of VLP. In contrast, mRNA with IRES failed due to modified nucleosides. Mice vaccinated with mRNAs that successfully expressed VLP developed neutralizing antibodies against EV-D68. They also demonstrated a protective effect against intranasal challenge, and their serum prevented neonatal mice from developing neurological symptoms caused by EV-D68 infection. These mRNA designs may reduce manufacturing complexity and cost, facilitating the development of effective EV-D68 mRNA vaccines.
No takes yet. Share an insight, caveat, or question.
Kunishima et al. (2026) studied Enterovirus D68 infection. Single-transcript mRNA vaccine expressing virus-like particles of enterovirus D68 was evaluated on Neutralizing antibodies against EV-D68 and protective effect against intranasal challenge. Mice vaccinated with single-transcript mRNA constructs encoding P1 and 3CD developed neutralizing antibodies against EV-D68 and demonstrated protection against intranasal challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: